Close Menu

NEW YORK (GenomeWeb) – Invitae and Alnylam Pharmaceuticals have together launched a free genetic testing service called Alnylam Act to encourage early testing and diagnosis for hereditary ATTR amyloidosis.

Through this program, funded by Alnylam, Invitae will perform free testing using one of its comprehensive gene panels for cardiomyopathy, neuropathy, or amyloidosis. Patients eligible for free testing are those in the US who are suspected to have the disease or a family history of it.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.